Neutralization of TNFα using either anti-TNFα antibodies or the soluble decoy receptor for TNFα has been instrumental in reducing the severity of arthritis, and a variety of biologics (e.g., infliximab, etanercept, etc.) based on this concept are currently being used in the clinic for the treatment of RA (Table 1). This evidence concerns the gene TNF and Arthritis.